Ramosetron in Irritable Bowel Syndrome with Diarrhea: New Hope or the Same Old Story?

Overview

Journal Clin Gastroenterol Hepatol

Specialty Gastroenterology

Date 2014 Jan 8

PMID 24393804

Citations 7

Authors

Madhusudan Grover

Michael Camilleri

Affiliations

Soon will be listed here.

Citing Articles

Exploring the Antidiarrheal Properties of Papaya Leaf: Insights Study in Mice-Model and Analysis at M3 Muscarinic Acetylcholine Receptor Interaction.

Saptarini N, Kelutur F, Corpuz M Scientifica (Cairo). 2024; 2024:1558620.

PMID: 38962530 PMC: 11221971. DOI: 10.1155/2024/1558620.

Evaluation of the gastrointestinal anti-motility effect of stem bark extract: A mechanistic study of antidiarrheal activity.

Omolaso B, Oluwole F, Odukanmi O, Adesanwo J, Ishola A, Adewole K J Pharm Anal. 2022; 11(6):776-782.

PMID: 35028183 PMC: 8740391. DOI: 10.1016/j.jpha.2020.06.009.

5-HT receptor signaling in serotonin transporter-knockout rats: a female sex-specific animal model of visceral hypersensitivity.

El-Ayache N, Galligan J Am J Physiol Gastrointest Liver Physiol. 2018; 316(1):G132-G143.

PMID: 30359082 PMC: 6383387. DOI: 10.1152/ajpgi.00131.2018.

Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.

Zheng Y, Yu T, Tang Y, Xiong W, Shen X, Jiang L PLoS One. 2017; 12(3):e0172846.

PMID: 28291778 PMC: 5349445. DOI: 10.1371/journal.pone.0172846.

Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.

Fukudo S, Kinoshita Y, Okumura T, Ida M, Hayashi K, Akiho H J Gastroenterol. 2016; 51(9):874-82.

PMID: 26800997 DOI: 10.1007/s00535-016-1165-5.

References

Hicks G, Coldwell J, Schindler M, Ward P, Jenkins D, Lynn P . Excitation of rat colonic afferent fibres by 5-HT(3) receptors. J Physiol. 2002; 544(3):861-9. PMC: 2290619. DOI: 10.1113/jphysiol.2002.025452. View

Andresen V, Montori V, Keller J, West C, Layer P, Camilleri M . Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2008; 6(5):545-55. PMC: 2587294. DOI: 10.1016/j.cgh.2007.12.015. View

Chiba T, Yamamoto K, Sato S, Suzuki K . Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2013; 6:123-8. PMC: 3728153. DOI: 10.2147/CEG.S32721. View

Cremonini F, Nicandro J, Atkinson V, Shringarpure R, Chuang E, Lembo A . Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. 2012; 36(5):437-48. PMC: 3464357. DOI: 10.1111/j.1365-2036.2012.05208.x. View

Prior A, Read N . Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1993; 7(2):175-80. DOI: 10.1111/j.1365-2036.1993.tb00087.x. View

Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D . A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion. 2008; 77(3-4):225-35. DOI: 10.1159/000150632. View

Berman S, Munakata J, Naliboff B, Chang L, Mandelkern M, Silverman D . Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain. 2000; 4(2):157-72. DOI: 10.1053/eujp.2000.0167. View

Miyata K, Kamato T, Nishida A, Ito H, Yuki H, Yamano M . Role of the serotonin3 receptor in stress-induced defecation. J Pharmacol Exp Ther. 1992; 261(1):297-303. View

Ford A, Brandt L, Young C, Chey W, Foxx-Orenstein A, Moayyedi P . Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009; 104(7):1831-43. DOI: 10.1038/ajg.2009.223. View

10.

Miyata K, Kamato T, Nishida A, Ito H, Katsuyama Y, Iwai A . Pharmacologic profile of (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H- benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine3 receptor antagonist, and its enantiomer in the isolated tissue. J Pharmacol Exp Ther. 1991; 259(1):15-21. View

11.

Viramontes B, Camilleri M, McKinzie S, Pardi D, Burton D, Thomforde G . Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001; 96(9):2671-6. DOI: 10.1111/j.1572-0241.2001.04138.x. View

12.

Camilleri M . Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?. Neurogastroenterol Motil. 2007; 19(2):77-84. DOI: 10.1111/j.1365-2982.2006.00861.x. View

13.

Tong K, Paul Nicandro J, Shringarpure R, Chuang E, Chang L . A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol. 2013; 6(5):344-57. PMC: 3756634. DOI: 10.1177/1756283X13491798. View

14.

Camilleri M . Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2013; 14(9):1151-60. DOI: 10.1517/14656566.2013.794223. View

15.

Naliboff B, Berman S, Chang L, Derbyshire S, Suyenobu B, Vogt B . Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology. 2003; 124(7):1738-47. DOI: 10.1016/s0016-5085(03)00400-1. View

16.

Miyata K, Ito H, Fukudo S . Involvement of the 5-HT3 receptor in CRH-induce defecation in rats. Am J Physiol. 1998; 274(5):G827-31. DOI: 10.1152/ajpgi.1998.274.5.G827. View

17.

Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S . Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil. 2008; 20(5):557-65. DOI: 10.1111/j.1365-2982.2007.01069.x. View

18.

Saslow S, Scolapio J, Camilleri M, Forstrom L, Thomforde G, Burton D . Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. Gut. 1998; 42(5):628-34. PMC: 1727117. DOI: 10.1136/gut.42.5.628. View

19.

Painsipp E, Shahbazian A, Holzer P . Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats. Br J Pharmacol. 2009; 158(5):1210-26. PMC: 2782331. DOI: 10.1111/j.1476-5381.2009.00392.x. View

20.

Bjornsson E, Chey W, Ladabaum U, Woods M, Hooper F, Owyang C . Differential 5-HT3 mediation of human gastrocolonic response and colonic peristaltic reflex. Am J Physiol. 1998; 275(3):G498-505. DOI: 10.1152/ajpgi.1998.275.3.G498. View